CU24272B1 - Derivados de tetrahidropirido-pirimidina como inhibidores de mek - Google Patents

Derivados de tetrahidropirido-pirimidina como inhibidores de mek

Info

Publication number
CU24272B1
CU24272B1 CUP2014000110A CU20140110A CU24272B1 CU 24272 B1 CU24272 B1 CU 24272B1 CU P2014000110 A CUP2014000110 A CU P2014000110A CU 20140110 A CU20140110 A CU 20140110A CU 24272 B1 CU24272 B1 CU 24272B1
Authority
CU
Cuba
Prior art keywords
compounds
mek inhibitors
tetrahydropirid
formula
pyrimidine derivatives
Prior art date
Application number
CUP2014000110A
Other languages
English (en)
Other versions
CU20140110A7 (es
Inventor
Rakesh Kumar Banerjee
Bhavesh Dave
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Rajender Kumar Kamboj
Abhijit Datta Khoje
Venkata P Palle
Samiron Phukan
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24272(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CU20140110A7 publication Critical patent/CU20140110A7/es
Publication of CU24272B1 publication Critical patent/CU24272B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente divulgación se relaciona con compuestos de heteroarilo como inhibidores de MEK. Estos compuestos incluyen compuestos de heteroarilo de Fórmula (I), sus sales farmacéuticamente aceptables, combinaciones con composiciones de medicamentos y farmacéuticas adecuadas de los mismos. La presente divulgación también incluye procesos para la preparación de los compuestos y su uso en métodos de tratamiento. Los compuestos tal como se divulgan en la presente son de la Fórmula (I) que figure a continuación: ESPACIO PARA FÓRMULA
CUP2014000110A 2012-03-14 2013-03-11 Derivados de tetrahidropirido-pirimidina como inhibidores de mek CU24272B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051908 WO2013136249A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors

Publications (2)

Publication Number Publication Date
CU20140110A7 CU20140110A7 (es) 2014-11-27
CU24272B1 true CU24272B1 (es) 2017-08-08

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
CUP2014000109A CU24335B1 (es) 2012-03-14 2013-03-11 Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
CUP2014000110A CU24272B1 (es) 2012-03-14 2013-03-11 Derivados de tetrahidropirido-pirimidina como inhibidores de mek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CUP2014000109A CU24335B1 (es) 2012-03-14 2013-03-11 Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer

Country Status (36)

Country Link
US (5) US9573944B2 (es)
EP (2) EP2834237B1 (es)
JP (3) JP6093384B2 (es)
KR (4) KR102241111B1 (es)
CN (4) CN107698585A (es)
AP (2) AP3834A (es)
AU (4) AU2013234009B2 (es)
BR (1) BR112014022713B1 (es)
CA (2) CA2865167C (es)
CL (2) CL2014002412A1 (es)
CO (2) CO7170131A2 (es)
CR (2) CR20140464A (es)
CU (2) CU24335B1 (es)
DK (2) DK2834236T3 (es)
DO (2) DOP2014000203A (es)
EA (2) EA029768B1 (es)
ES (2) ES2684517T3 (es)
GE (2) GEP201706671B (es)
GT (2) GT201400196A (es)
HK (2) HK1202538A1 (es)
IL (2) IL234560A (es)
IN (2) IN2014MN01754A (es)
MA (2) MA37405A1 (es)
MX (3) MX366426B (es)
MY (2) MY175950A (es)
NI (2) NI201400107A (es)
NZ (2) NZ629442A (es)
PE (2) PE20141973A1 (es)
PH (2) PH12014502041B1 (es)
PL (1) PL2834237T3 (es)
SG (2) SG11201405006PA (es)
TN (2) TN2014000357A1 (es)
TR (1) TR201811976T4 (es)
UA (2) UA114907C2 (es)
WO (2) WO2013136254A1 (es)
ZA (1) ZA201406186B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013136254A1 (en) 2012-03-14 2013-09-19 Lupin Limited Heterocyclyl compounds
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
CA2927635C (en) 2013-10-25 2021-07-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10898487B2 (en) 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202005881YA (en) * 2017-12-21 2020-07-29 Boehringer Ingelheim Int Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
DK3788047T3 (da) 2018-05-04 2024-09-16 Incyte Corp Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
EP3986408A1 (en) 2019-06-19 2022-04-27 Boehringer Ingelheim International GmbH Anticancer combination therapy
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220106106A (ko) * 2019-07-30 2022-07-28 에드빈세 아베 뇌졸중 치료용 mek 억제제
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4157836A1 (en) 2020-06-02 2023-04-05 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
US20240238294A1 (en) 2021-04-09 2024-07-18 Boehringer Ingelheim International Gmbh Anticancer therapy
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AU2022258968A1 (en) * 2021-04-16 2023-10-19 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4441054A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN118591540A (zh) 2021-12-01 2024-09-03 勃林格殷格翰国际有限公司 包含环状2-氨基-3-氰基噻吩的kras降解化合物
EP4441050A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CA3240980A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2005051302A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
CN101912400B (zh) * 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP2012524114A (ja) 2009-04-21 2012-10-11 ノバルティス アーゲー Ｍｅｋ阻害剤としてのヘテロ環式化合物
WO2013136254A1 (en) * 2012-03-14 2013-09-19 Lupin Limited Heterocyclyl compounds

Also Published As

Publication number Publication date
AU2013234009A1 (en) 2014-09-25
AU2018202568A1 (en) 2018-05-10
US20150299186A1 (en) 2015-10-22
CN104271577A (zh) 2015-01-07
IL234559A (en) 2017-06-29
AP3834A (en) 2016-09-30
CA2865164A1 (en) 2013-09-19
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
HK1202538A1 (en) 2015-10-02
GT201400195A (es) 2017-11-09
US20170112840A1 (en) 2017-04-27
NZ629432A (en) 2017-01-27
IL234560A (en) 2017-06-29
IN2014MN01754A (es) 2015-07-03
US9969731B2 (en) 2018-05-15
TR201811976T4 (tr) 2018-09-21
US20170101408A1 (en) 2017-04-13
EA201491671A1 (ru) 2014-12-30
US9573944B2 (en) 2017-02-21
MX355526B (es) 2018-04-20
EP2834236A1 (en) 2015-02-11
CN107698585A (zh) 2018-02-16
MA37405A1 (fr) 2016-03-31
US20150133424A1 (en) 2015-05-14
AU2013234009B2 (en) 2016-10-27
DOP2014000204A (es) 2015-02-15
MX2014010925A (es) 2015-04-10
JP2015514056A (ja) 2015-05-18
PH12014502040B1 (en) 2014-11-24
JP2018115215A (ja) 2018-07-26
MY174188A (en) 2020-03-12
WO2013136249A1 (en) 2013-09-19
EA028232B1 (ru) 2017-10-31
KR102241111B1 (ko) 2021-04-15
EA029768B1 (ru) 2018-05-31
CL2014002412A1 (es) 2015-03-06
AU2013234014A1 (en) 2014-09-25
CL2014002411A1 (es) 2015-04-06
ZA201406186B (en) 2016-06-29
EP2834237A1 (en) 2015-02-11
BR112014022713B1 (pt) 2021-09-08
MX2014010928A (es) 2015-04-10
WO2013136254A1 (en) 2013-09-19
CR20140463A (es) 2014-11-28
MA37400A1 (fr) 2016-05-31
CA2865167A1 (en) 2013-09-19
JP6093384B2 (ja) 2017-03-08
HK1206020A1 (en) 2015-12-31
TN2014000357A1 (en) 2015-12-21
KR20190073597A (ko) 2019-06-26
MX355474B (es) 2018-04-16
CU24335B1 (es) 2018-04-03
DK2834236T3 (da) 2019-08-26
DK2834237T3 (en) 2018-08-27
JP2015509975A (ja) 2015-04-02
UA114907C2 (uk) 2017-08-28
AP2014008008A0 (en) 2014-10-31
PH12014502041A1 (en) 2014-11-24
MX366426B (es) 2019-07-08
NZ629442A (en) 2016-12-23
AU2017200493B2 (en) 2018-03-29
AU2013234014B2 (en) 2017-02-02
PL2834237T3 (pl) 2018-11-30
NI201400108A (es) 2014-11-28
SG11201405007QA (en) 2014-10-30
EP2834237B1 (en) 2018-06-06
KR20140138910A (ko) 2014-12-04
KR20140138911A (ko) 2014-12-04
MA37400B1 (fr) 2019-11-29
ES2741896T3 (es) 2020-02-12
CO7170131A2 (es) 2015-01-28
AP2014008009A0 (en) 2014-10-31
BR112014022713A2 (es) 2017-06-20
EP2834236B1 (en) 2019-05-22
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
PE20141974A1 (es) 2014-12-12
PE20141973A1 (es) 2014-12-12
KR102240101B1 (ko) 2021-04-14
KR20190100472A (ko) 2019-08-28
CN108383836B (zh) 2021-11-12
JP6630771B2 (ja) 2020-01-15
ES2684517T3 (es) 2018-10-03
PH12014502040A1 (en) 2014-11-24
GEP201706671B (en) 2017-05-25
NI201400107A (es) 2014-11-26
US9827247B2 (en) 2017-11-28
PH12014502041B1 (en) 2014-11-24
CR20140464A (es) 2014-11-28
UA114906C2 (uk) 2017-08-28
GEP201706774B (en) 2017-11-27
AU2018202568B2 (en) 2019-05-09
US9555035B2 (en) 2017-01-31
IN2014MN01755A (es) 2015-07-03
JP6431770B2 (ja) 2018-11-28
CU20140110A7 (es) 2014-11-27
GT201400196A (es) 2017-09-28
US9428499B2 (en) 2016-08-30
CU20140109A7 (es) 2014-11-27
US20160331753A1 (en) 2016-11-17
SG11201405006PA (en) 2014-10-30
DOP2014000203A (es) 2015-02-15
AU2017200493A1 (en) 2017-02-16
CN108383836A (zh) 2018-08-10
CN104203947A (zh) 2014-12-10
CA2865167C (en) 2019-08-06
CA2865164C (en) 2021-06-08
AP3859A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
CU24272B1 (es) Derivados de tetrahidropirido-pirimidina como inhibidores de mek
ECSP14013215A (es) Compuestos novedosos
CU20130129A7 (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
CR20150045A (es) Inhibidores de hepatitis c
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
CR20130543A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20120443A (es) Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
NI201500054A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
ECSP15013883A (es) Benzamidas
CR20170468A (es) Compuestos novedosos
UY33490A (es) Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos.
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
DOP2013000284A (es) Derivados de pirazol útiles como inhibidores de aldosterona sintasa
ECSP15015088A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211